Related Experiment Video

Updated: Jun 4, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K

Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021

Pojsakorn Danpanichkul1, Kanokphong Suparan2, Chuthatip Kaeosri3

  • 1Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|December 18, 2024
PubMed
Abstract

Insights

The global burden of primary liver cancer (PLC) linked to metabolic dysfunction-associated steatohepatitis (MASH) has significantly increased over two decades. Urgent global strategies are needed to address MASH-associated PLC and its metabolic drivers, considering existing disparities.

Area of Science:

  • Hepatology
  • Global Health
  • Cancer Epidemiology

Background:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are primary drivers of liver disease and increasingly linked to primary liver cancer (PLC).
  • Updated global data on MASH-associated PLC are crucial for understanding disease burden and trends.

Purpose of the Study:

  • To analyze global trends in the incidence, mortality, and disability-adjusted life years (DALYs) of MASH-associated PLC from 2000 to 2021.
  • To identify geographic, sociodemographic, age, and sex disparities in MASH-associated PLC burden.

Main Methods:

  • Utilized the Global Burden of Disease study data spanning 2000-2021.
  • Assessed age-standardized incidence, mortality, and DALYs for MASH-associated PLC.
  • Stratified analyses by region, sociodemographic index, age, and sex.

Main Results:

  • Global incidence, deaths, and DALYs from MASH-associated PLC rose significantly (98%, 93%, and 76% respectively).
  • MASH-associated PLC demonstrated increasing mortality rates, unlike other etiologies.
  • Africa and low sociodemographic index countries bore the highest burden; the Americas showed the fastest growth in incidence and mortality.

Conclusions:

  • The burden of MASH-associated PLC has substantially increased globally over the past two decades.
  • Significant sociodemographic and geographic disparities exist, highlighting inequities in disease impact.
  • Urgent, coordinated global strategies are imperative to combat the MASH-associated PLC epidemic and its underlying metabolic factors.
Keywords:
CancerEpidemiologyLiver CancerMetabolic Dysfunction-associated Steatotic Liver DiseaseNonalcoholic Fatty Liver Disease

More Related Videos

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula09:03

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

336
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
450
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328